country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-P992541

Copy Link Print Information

IBI3003

IBI3003 is a trispecific antibody targeting GPRC5D/BCMA/CD3. IBI3003 can redirect T cells to BCMA/GPRC5D-expressing multiple myeloma cells. IBI3003 is designed to overcome single tumor antigen escape caused by low expression of BCMA and GPRC5D. IBI3003 can be used in research on relapsed/refractory multiple myeloma.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

IBI3003 Chemical Structure

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Use of MCE Products

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Species Reactivity
- In Vitro
- Target
- Conjugated
- Anwendung
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Species Reactivity

Human

In Vitro

Anti-cancer

IBI3003 is a trispecific antibody targeting GPRC5D, BCMA, and CD3, designed to counteract single-antigen-mediated tumor escape; it exhibits potent cytotoxic activity against multiple myeloma with low BCMA and GPRC5D expression^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Related Protocols :

RNA extraction experimental

Target

GPRC5D & BCMA & CD3

Conjugated

Unconjugated

Anwendung

ELISA, FACS, Functional assay

Chemical Information

SMILES

[IBI3003]
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Inhibitory Antibodies User Guide (603 KB)

Verweise

[1]. Li J, et al. Initial Results of the first-in-human Phase 1 study of IBI3003, a novel trispecific antibody targeting GPRC5D, BCMA and CD3, in patients with relapsed or refractory multiple myeloma. Blood. 2025;146(Supplement 1):702.

[2]. van de Donk N W C J. Dual-antigen-targeting T-cell immunotherapies in MM: circumventing tumor heterogeneity and preventing antigen escape. Blood. 2026;147(19):2176-2193.

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Bioz

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen